X hits on this document

146 views

0 shares

0 downloads

0 comments

29 / 39

12.2

10.5

12.0

21.0

21.0

1.0

26.0

4.0

1991

12.5

20.8

4.7

5.5

10.4 4.8

4.4

1996

15.6

35.4

6.7

5.3

24.0

11.9

8.0

2001

13.1

21.0

4.4

9.5

15.0

4.0

4.5

2001

15.6

35.4

6.7

5.3

24.0

11.9

8.0

2002

19.4

46.1

9.1

6.0

15.4

4.4

5.5

2002

18.0

36.5

8.1

6.0

21.9

15.6

11.3

2004

23.2

41.0

9.9

8.0

23.1

7.9

8.6

2004

23.2

41.0

9.9

8.0

23.1

7.9

19.0

2004

20.3

45.0

10.6

8.0

34.0

1.0

1.0

1996

9.5

15.0

4.2

16.0

31.0

17.0

12.0

]

Regimen First-line therapies 5-FU + Leucovorin

Irinotecan (Camptosar) + 5- FU/LV

Capecitabine (Xeloda)

Irinotecan + capecitabine

Oxaliplatin (Eloxatin) + 5-FU/LV

Oxaliplatin + capecitabine

Bevacizumab (Avastin) + oxaliplatin + 5-FU/LV Bevacizumab + oxaliplatin

  • +

    capecitabine

Bevacizumab + irinotecan

  • +

    5-FU/LV

Second-line therapies Irinotecan

39.5

11.0

38.8

4.4

3.7

8.0

Table 1: Attributes of the Drug Regimens

39.5

11.0

3.0

2.5

33.7 4.0

Efficacy Measures

Grade 3 or Grade 4 Side Effects (%)

Vomi-

Neutro- Dehy-

ting

penia dration

Launch Survival Response

Year

Months

Rate

Time to Progression

Abdominal Pain

Diarrhea Nausea

Cetuximab (Erbitux)

2004

N/A

10.8

1.5

9.0

2.0

2.0

3.0

5.0

3.0

Cetuximab + irinotecan

2004

N/A

22.9

4.1

8.0

22.0

6.0

7.0

5.0

6.0

17

Document info
Document views146
Page views146
Page last viewedWed Jan 25 02:54:59 UTC 2017
Pages39
Paragraphs850
Words10609

Comments